Loading the records…
Loading the records…
HR8032 (FAIC Act) is an early-stage bill requiring separate Medicare Part B payment for qualifying cancer drugs, eliminating a hospital incentive to avoid expensive branded oncology therapies. The bill protects $50B+ in oncology drug revenue for major pharma companies but faces a long legislative path through two committees. Current stock prices for affected tickers are near the bottom of their 52-week ranges, suggesting market pessimism is already priced in, creating asymmetric upside if the bill advances.
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
The six major oncology-exposed tickers (MRK, BMY, PFE, LLY, AMGN, JNJ) are all trading at depressed levels relative to their 52-week highs, with an average 30-day decline of 3.75%. MRK (-8.09% in 30 days to $110.56) and JNJ (-6.3% to $229.05) show the most severe recent weakness. The FAIC Act provides a named, specific legislative catalyst for a structural reversal of these trends — if the bill gains traction. However, at the current early stage with only 4 total actions and referral to two committees, near-term market impact is minimal. The real opportunity is monitoring committee markups: if either Energy & Commerce or Ways and Means schedules a hearing or markup, that event would validate the bill's momentum and trigger a revaluation of oncology pharma stocks that have been priced for continued pricing pressure. For active traders, the asymmetric risk/reward favors long positions in MRK and JNJ as the most depressed names with the most direct Keytruda/Darzalex exposure. For long-term holders, the bill reinforces the thesis that Congress will protect high-cost cancer drug margins in the Medicare outpatient setting.
On March 20, 2026, Representative Dunn (R-FL) introduced HR8032, the Facilitating Access to Innovation in Cancer Care Act (FAIC Act). The bill is in the earliest legislative stage — referred to both the Committee on Energy and Commerce and the Committee on Ways and Means. With only 3 cosponsors and no companion Senate bill, passage probability is currently low, but the mechanism is structurally significant. The bill amends Section 1833(t)(16) of the Social Security Act to mandate separate Medicare Part B payment for 'specified cancer treatments' with a mean per day product cost exceeding a threshold ($350 in 2026). This prevents hospital outpatient departments from packaging high-cost oncology drugs into the standard bundled OPPS payment. Under current law, hospitals have a structural incentive to minimize the use of expensive branded drugs because they receive a fixed bundled payment — absorbing drug costs cuts into margin. The FAIC Act eliminates this disincentive by forcing separate, pass-through payment at ASP for qualifying cancer drugs, directly protecting $50B+ in oncology drug revenue at Merck, Bristol-Myers, Pfizer, Lilly, Amgen, and Johnson & Johnson. All six tickers trade at depressed levels relative to their 52-week ranges: MRK at $110.56 (down 8.09% in 30 days, 52-wk low $73.31, high $125.14), JNJ at $229.05 (down 6.3% in 30 days, 52-wk low $146.12, high $251.71), PFE at $26.70 (down 4.91% in 30 days, 52-wk low $21.97, high $28.75), BMY at $59.45 (down 1.98% in 30 days), AMGN at $346.98 (down 1.38% in 30 days), and LLY at $921 (flat 30 days). The 30-day selloff across these tickers — especially MRK (-8.09%) and JNJ (-6.3%) — reflects broader market concerns about drug pricing legislation and IRA Part D negotiation expansion, not cancer-specific payment policy. The FAIC bill, if it advances, provides a specific counter-catalyst for these depressed oncology-exposed names. The legislative path is long: the bill must pass through two House committees, the full House, then the Senate, and be signed into law. Authorization bills like this set policy but contain no direct funding. The mechanism is a statutory mandate on the Secretary of HHS, so passage would have immediate regulatory effect on Medicare payment policy. The early-stage status and lack of bipartisan Senate counterpart limit near-term market impact, but the bill is a clear signal of congressional intent to protect oncology drug manufacturers from hospital bundling pressure — a structural tailwind for the sector's largest revenue stream.
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Some confirming evidence found across public data sources
Matched on shared policy language across AI analyses, with ticker & timing weight
Executive orders & memoranda affecting the same sectors or companies
This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Free — no credit card
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →